Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

BeneChill Closes $13.5 Million Series C Financing For Early Commercialization Of The RhinoChill Device

BeneChill has raised a $13.5 million Series C financing led by New investor HealthCap (Stockholm). The other participants were Series A and B investors MedVenture Associates, the Solon Foundation and NGN Capital. Proceeds will be used to fund early commercialization of the RhinoChill device.

The company has recently completed a randomized PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) study of the RhinoChill device in cardiac arrest patients. The study will determine if the addition of intra-nasal cooling during resuscitation improves outcome following cardiac arrest over the hospital-based cooling alone. BeneChill will present the results of the PRINCE trial at the American Heart Association’s Scientific Sessions.